Question explored with the scientific record
is ivermectin effective against cancer?
The short version: ivermectin kills cancer cells in dishes and in mice, but no human trial has tested it as a cancer treatment.
Every study here is preclinical. Ivermectin triggers multiple cell-death pathways in cancer lines: it blocks AKT/mTOR and WNT signaling [5, 3], disrupts mitochondrial function [10], and activates inflammatory cell death through P2X4/P2X7 receptors [4]. In mouse models, it shrinks breast tumors [2], gliomas [6], and esophageal cancer [10]. A 2025 nanoformulation study in rats showed a 70% reduction in glioma volume with intranasal ivermectin [6]. Another 2025 study combined ivermectin with a manganese-dioxide nanoparticle and achieved 99% tumor inhibition in a mouse liver cancer model [14].
None of this is human clinical evidence. The concentrations that kill cancer cells in the lab are in the low micromolar range [4, 10]. Human blood levels after standard oral doses peak in the nanomolar range, roughly 10 to 100 times lower [13]. The same 2025 paper that flagged this gap showed that ivermectin's antiviral activity in cell culture was driven by nonspecific membrane disruption that overlaps with cell toxicity, not a targeted mechanism [13]. That same problem likely applies to the cancer data.
| Setting | What was tested | Result | Evidence |
|---|---|---|---|
| Cell lines (breast, glioma, esophageal, liver) | Ivermectin alone or in nanoformulations | IC50 2–16 µM; multiple death pathways activated | [2, 4, 5, 10] |
| Mouse xenografts (breast, glioma, liver) | Ivermectin or nano-ivermectin | Tumor volume reduction 70–99% | [2, 6, 14] |
| Human blood levels at approved doses | Oral ivermectin 12–24 mg | Cmax 30–300 nM (0.03–0.3 µM) | [13] |
| Human cancer trials | None | No data | — |
The gap between the concentrations that work in the lab and what the human body can safely achieve is roughly 10- to 100-fold. Nanoformulations may narrow that gap, but they have not been tested in humans for cancer. The evidence for ivermectin as a human cancer treatment is zero clinical trials, a strong mechanistic signal, and a pharmacokinetic problem that has not been solved.
My call: ivermectin shows real anticancer activity in preclinical models, but no human trial has tested it, and the doses needed may exceed what is safe by mouth. Confidence: low for human use, high for the preclinical mechanism.
Sources used 8
-
Biomimetic platelet-membrane camouflaged ivermectin nanocrystals for tumor homing and breast cancer management
The study develops biomimetic platelet-membrane camouflaged ivermectin nanocrystals (PMV/Ivm-NC) using a sonoprecipitation method and platelet membrane coating to achieve targeted tumor homing, immunogenic cancer cell death, and enhanced antitumor/antimetastatic effects against …
DOI: 10.1007/s13346-025-02032-2 -
Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling
The study shows that repurposed anthelmintic ivermectin inhibits canine mammary tumor growth by causing G1 cell cycle arrest via downregulation of cyclin D1 and CDK4 and by suppressing WNT/β-catenin signaling, with efficacy observed in vitro in canine mammary tumor cell lines an…
DOI: 10.1186/s12917-019-2026-2 -
Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death
Augmenting extracellular ATP signaling through P2X4/P2X7/Pannexin-1 with Ivermectin drives a rapid, inflammatory cancer cell death in breast cancer cells, combining necrotic/pyroptotic and apoptotic pathways via ROS/CaMKII/MPTP and autophagy, with immunogenic-cell-death hallmark…
DOI: 10.1038/srep16222 -
Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells
Ivermectin triggers autophagy through AKT/mTOR inhibition in glioma cells; autophagy protects against IVM-induced apoptosis in vitro, and combining with chloroquine enhances anti-glioma effects in vivo.
DOI: 10.1042/bsr20192489 -
Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression
This study demonstrates nose-to-brain delivery of ivermectin nanocarriers (polymeric nanocapsules and mesoporous silica particles) to suppress glioma growth in a rat model, with intranasal polymeric nanocapsules significantly reducing tumor size and improving histology at a clin…
DOI: 10.1021/acsbiomaterials.5c00642 -
Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway
Ivermectin inhibits ESCC proliferation in vitro and in vivo by inducing mitochondrial dysfunction, ROS accumulation, NF-κB inhibition, and apoptosis via the mitochondrial pathway.
DOI: 10.1186/s12885-021-09021-x -
Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV-2 Antiviral Activities and Lack of Translatability
This Perspective demonstrates that ivermectin’s in vitro SARS-CoV-2 antiviral activity is driven by nonspecific membrane perturbation and assay interference, tightly correlates with host cell toxicity, and fails to translate clinically due to pharmacokinetic constraints and lack…
DOI: 10.1021/acs.jmedchem.5c01610 -
Purinergic Receptor Nanoimmunoamplifiers Potentiate Chemoimmunotherapy Efficacy in Hepatocellular Carcinoma
A novel ivermectin–MnO2 nanoimmunoamplifier (IMN) was designed to potentiate chemoimmunotherapy for hepatocellular carcinoma by sustaining eATP signaling through P2X4R/P2X7R, alleviating tumor hypoxia, reducing eATP degradation via CD39/CD73, and robustly activating the NLRP3 in…
DOI: 10.34133/bmr.0278